Tara M. Babu

Tara M. Babu

Auto-generated profile, based on publicly available information

Tara M. Babu

Department of Medicine, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2014 in Vaccine
Verified
Journal Article
Closed access
TBTara M. Babu
Tara M. Babu
MLMin Levine
Min Levine
TFTheresa Fitzgerald
Theresa Fitzgerald
CLCatherine Luke
Catherine Luke
MSMark Sangster
Mark Sangster
KSKanta Subbarao
Kanta Subbarao

11 July 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KLKirsten E. Lyke
Kirsten E. Lyke
RARobert L. Atmar
Robert L. Atmar
CIClara Dominguez Islas
Clara Dominguez Islas
CPChristine M. Posavad
Christine M. Posavad
MDMeagan E. Deming
Meagan E. Deming
JWJennifer A. Whitaker
Jennifer A. Whitaker
: As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.

14 July 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
TBTara M Babu
Tara M Babu
LFLeora R Feldstein
Leora R Feldstein
SSSharon Saydah
Sharon Saydah
ZAZachary Acker
Zachary Acker
CBCassandra L Boisvert
Cassandra L Boisvert
ANAllison L Naleway
Allison L Naleway
Introduction Although SARS-CoV-2 vaccines were first approved under Emergency Use Authorization by the Food and Drug Administration in late 2020 for adults, authorisation for young children 6 months to 6 months and adults aged <50 years. Methods CASCADIA is a 4-year community-based prospective study of SARS-CoV-2 VE among 3500 adults and paediatric populations aged 6 months to 49 years in Oregon and Washington, USA. At enrolment and regular intervals, participants complete a sociodemographic questionnaire. Individuals provide a blood sample at enrolment and annually thereafter, with optional blood draws every 6 months and after infection and vaccination. Participants complete weekly self-collection of anterior nasal swabs and symptom questionnaires. Swabs are tested for SARS-CoV-2 and other respiratory pathogens by reverse transcription-PCR, with results of selected pathogens returned to participants; nasal swabs with SARS-CoV-2 detected will undergo whole genome sequencing. Participants who test positive for SARS-CoV-2 undergo serial swab collection every 3 days for 21 days. Serum samples are tested for SARS-CoV-2 antibody by binding and neutralisation assays. Analysis The primary outcome is SARS-CoV-2 infection. Cox regression models will be used to estimate the incidence rate ratio associated with SARS-CoV-2 vaccination among the paediatric and adult population, controlling for demographic factors and other potential confounders. Ethics and dissemination All study materials including the protocol, consent forms, data collection instruments, participant communication and recruitment materials, were approved by the Kaiser Permanente Interregional Institutional Review Board, the IRB of record for the study. Results will be disseminated through peer-reviewed publications, presentations, participant newsletters and appropriate general news media.

11 March 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
SCSarah Cox
Sarah Cox
PRPavitra Roychoudhury
Pavitra Roychoudhury
CFCollrane Frivold
Collrane Frivold
ZAZack Acker
Zack Acker
TBTara M Babu
Tara M Babu
HCHelen Y Chu
Helen Y Chu
Background: Household transmission of respiratory viruses may drive community spread. Few recent studies have examined household respiratory syncytial virus (RSV) transmission in the United States. Methods: We conducted a prospective community-based cohort study from 1 June 2022 to 31 May 2023. Participants had blood samples collected and completed nasal swabs and surveys at least weekly, irrespective of symptoms. We tested serum for RSV antibody, nasal swabs by quantitative reverse transcription polymerase chain reaction (RT-qPCR), and performed whole genome sequencing. We evaluated secondary RSV transmission and associated risk factors based on a log-linear Poisson regression model. Results: RSV was detected among 310 (10%) participants within 200 (20%) households. Most (94%) index cases were symptomatic. We identified 37 cases of potential secondary transmission within 14 days of a distinct index case (10%, 95% confidence interval [CI]: 7%, 14%); median age of index and secondary cases were 6 (interquartile range [IQR]: 3–10) and 35 (7–41) years, respectively, with 89% (24/27) of index cases aged 6 months to 12 years. Factors associated with increased risk of RSV transmission included index case viral detection ≥1 week and contact age ≤12 years. Of 120 sequenced specimens, the main lineages represented were A.d.5.2 (n = 37) and A.d.1 (n = 30). Sequenced viruses from households with ≥2 RSV infections were similar when occurring within ≤14 days (mean pairwise difference 4 [range 0–13], n = 17 households), compared to those >14 days (137 [37–236], n = 2). Conclusions: Most RSV household transmission occurs from infants and young children to adults. Viral genome sequencing demonstrated that multiple household infections within a 14-day period are likely due to within-household transmission.

26 June 2025 in Journal of Infection
Verified
Journal Article
Open access
RKRaj Kalkeri
Raj Kalkeri
MZMingzhu Zhu
Mingzhu Zhu
SCShane Cloney-Clark
Shane Cloney-Clark
APAnand Parekh
Anand Parekh
DGDrew Gorinson
Drew Gorinson
JPJoyce S. Plested
Joyce S. Plested

29 April 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
RARobert L. Atmar
Robert L. Atmar
KLKirsten E Lyke
Kirsten E Lyke
CPChristine M Posavad
Christine M Posavad
MDMeagan E Deming
Meagan E Deming
RBRebecca C Brady
Rebecca C Brady
PRPaul C Roberts
Paul C Roberts
Background: Mucosal immunity plays a critical role in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and replication. Understanding the capacity of coronavirus disease 2019 (COVID-19) vaccines to elicit both mucosal and systemic antibodies could help optimize vaccination strategies. Methods: We conducted an open-label, phase 1/2 adaptive-design clinical trial to evaluate the safety and immunogenicity of COVID-19 immunizations. Healthy adults received 2 priming doses of mRNA-1273, a booster dose of mRNA-1273, and a second booster of bivalent (WA-1 and BA.4/BA.5) mRNA-1273.222. Adverse event data were collected. Serum and mucosal immunity were evaluated. Results: One hundred six persons were enrolled. Thirty received all 4 study-related vaccine doses. All vaccines were well tolerated, with injection site pain, malaise, myalgias, and headache being the most frequently reported symptoms. Among those who received a second booster, 24 of 30 (80%) had serological evidence of SARS-CoV-2 infection. Following the second booster, increases in geometric mean binding and pseudovirus neutralization antibody titers to the ancestral strain and BA.1 and BA.5 variants were observed. Increases in mucosal immunoglobulin G and immunoglobulin A (IgA) antibodies in nasal and salivary samples were observed in both previously infected and infection-naive participants, although prior infection markedly boosted virus-specific mucosal IgA responses. Conclusions: The mRNA-1273.222 booster vaccine was safe and immunogenic and induced mucosal antibody responses in previously infected and infection-naive persons. Clinical Trials Registration: NCT04889209.